SETBP1 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain SETBP1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

SETBP1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains SETBP1 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

SETBP1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains SETBP1 status and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SETBP1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains SETBP1 status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SETBP1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains SETBP1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SETBP1 is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 0 are open and 1 is closed. Of the trial that contains SETBP1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (0 open) [4].